It also begs the question as to why Imugene opted to target patients who have failed Autologous CAR-T treatments in the same indication/s. What Grok offers up as an explanation points to a highly strategic approach that could beat Allogene on the "ahead of the market" front (in a clever roundabout way):-
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $179.4K | 14.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 15731879 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3477305 | 21 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |